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Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal
exposure with twice-daily dosing
Dolutegravir is licenced for use in both adults and
children over 12 years of age, although data are limited on
its use in pregnant women. The manufacturer suggests
that dolutegravir should be used in pregnancy only if the
benefits outweigh the risks [1]. UK and US guidelines
state that there are insufficient data to make recommen-
dations on its use in pregnancy [2,3]. Nevertheless there
are sporadic case reports of successful use in pregnant
women [4,5] with significant placental transfer suggested
by ex-vivo models [6] and a case report in vivo [5].
However, the effect of pregnancy on dolutegravir
pharmacokinetics and optimal dosing during pregnancy
is unknown. Here, we present our early experience of
dolutegravir pharmacokinetics in two pregnant women,
including the first published report of truncated 8-h
pharmacokinetic profiles of dolutegravir in the first and
third trimesters, in addition to measurement of foetal
dolutegravir levels in umbilical cord blood.
Our unit has treated two pregnant women with
dolutegravir, in both cases with extensive drug resistance
where dolutegravir was justified to prevent onward
transmission. The first was a 23-year-old woman whowas
referred in April 2015 for HIV management when she
was 9 weeks pregnant, with a CD4 cell count of 158 cells/
ml and a HIV viral load of 563 343 copies/ml. She was
previously known to our services and had been well
controlled on efavirenz and coformulated abacavir/
lamivudine until September 2014 when she was lost to
follow-up. Genotypic resistance testing showed X4
tropic virus with multiclass resistance to NRTIs and
NNRTIs, but no protease or integrase resistance
mutations. To aid adherence, she was commenced on a
once q.d. regimen of darunavir/ritonavir (800mg/
100mg) and dolutegravir (50mg). Her HIV-1 viral load
dropped to less than 30 copies/ml after 4 weeks. The drug
was well tolerated.
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Eight hour truncated pharmacokinetic profiling of
dolutegravir was carried out at week 13 gestation
(Fig. 1). This showed a peak dolutegravir concentration
(Cmax) of 4006 ng/ml, in excess of the mean Cmax of
3400 ng/ml in the SPRING-1 study for nonpregnant
adults taking 50mg q.d. of dolutegravir, and well above
the protein-binding corrected IC90 of 64 ng/ml for wild-
type virus [7]. Area under the curve over 0–8 h (AUC0–8)
was 15.9mg.h/ml.
Despite this, she experienced two rebounds in viral load
to 625 and 325 copies/ml, in the context of significant
medical problems (a pulmonary embolus and hydrone-
phrosis complicated by bacteraemia). We addressed
adherence concerns and her treatment was changed, at
22 weeks of gestation, to b.i.d. darunavir/ritonavir (600/
100mg) and twice daily dolutegravir (50mg) in the
anticipation that exposure to DTG would be reduced in
the third trimester. Her viral load resuppressed and repeat
pharmacokinetic profiling at 32 weeks of gestation
(Fig. 1) showed a Cmax of 3334 ng/ml, with AUC0-8
13.5mg.h/ml, a reduction of 15%.
She delivered a healthy baby by planned caesarean section
at 39 weeks of gestation; dolutegravir concentrations at
delivery (13 h postdose) were 1730 ng/ml in maternal
blood and 2211 ng/ml in cord blood, suggesting
significant in-utero exposures. On review at 8 weeks,
mother and baby were well; the baby’s T and B cell
numbers were normal, and are thus far uninfected.
The second woman, aged 27, had poor engagement with
services; she was presented in September 2015 at 31 weeks
of gestation in her third pregnancy, with a CD4 cell count
of 124 cells/ml and HIV-1 viral load of 235 copies/ml. She
was last seen a year previously following delivery of her
second child. At that time, she was virologically supressed
on zidovudine, lamivudine, raltegravir, and lopinavir/
ritonavir, but had subsequently defaulted from clinic
attendance. In view of her late presentation and uncertain
resistance profile, she was started on b.i.d. dolutegravir
(50mg) and darunavir/ritonavir (600mg/100mg), and
once q.d. coformulated tenofovir/emtricitabine (300mg/
200mg).Thiswaswell tolerated and4weeks later herHIV-
1 viral load was undetectable. She delivered a healthy baby
in November 2015 at 38 weeks of gestation by planned
caesarean section. Dolutegravir concentration in umbilical
cord blood was 1281 ng/ml, again suggesting significant
in-utero exposures. On review at 6 weeks, the baby was
well, and is thus far uninfected. We have reported both
cases to the antiretroviral pregnancy registry (http://
www.apregistry.com/Default.aspx) and follow-up of both
mothers and babies is on-going.
In conclusion, we present the first detailed pharmaco-
kinetic profile of dolutegravir in pregnancy, and confirm
significant foetal exposure at a dose of 50mg b.i.d.. The
effects of this level of in-utero exposure are unknown, but
we suggest caution with b.i.d. dolutegravir dosing; if this
dose is used, we suggest careful follow-up to assess for
toxicity in the child. Further studies of dolutegravir in
pregnancy are necessary to define the dosing schedule and
assess safety.
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Fig. 1. Serum dolutegravir levels pre and postdose in 1st
trimester (13weeks of gestation) and 3rd trimester (32weeks
of gestation). DTG¼dolutegravir, q.d.¼once-daily, b.i.d.¼
twice-daily, IC90¼ inhibitory concentration for 90% of viral
growth. Dolutegravir concentrations were measured by liquid
chromatography with tandem mass spectrometry after resol-
ving the glucuronidated dolutegravir from parent compound.
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